Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjdementia
VJNeurology
Logo
  • Home (current)
  • Diseases
    Parkinson's Disease
    Multiple Sclerosis and Related Disorders
    Headache
    Amyotrophic Lateral Sclerosis
    Epilepsy
    Sleep Disorders
    Stroke
    Neuromuscular Disorders
    Movement Disorders
    View all Diseases
  • Topics
    Biology
    Diagnostics
    Trial Updates
    Treatment
    Prevention
    Surgery
    Imaging
    Genetics
    COVID-19
    View all Topics
  • Conferences
    EHC 2022
    AES 2022
    WSC 2022
    ECTRIMS 2022
    EHDN 2022
    MDS 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

AMX0035

The pipeline of late-stage therapeutic options for patients with ALS 1:49
The pipeline of late-stage therapeutic options for patients with ALS
Matthew Kiernan • 4 Apr 2022
Personalizing therapy: the future of ALS treatment 1:48
Personalizing therapy: the future of ALS treatment
Nigel Leigh • 17 Mar 2022
AMX0035 in ALS: long-term survival analysis of the CENTAUR trial 3:40
AMX0035 in ALS: long-term survival analysis of the CENTAUR trial
Sabrina Paganoni • 15 Apr 2021
A new era in the discovery of ALS treatments 0:56
A new era in the discovery of ALS treatments
Sabrina Paganoni • 15 Apr 2021
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJNeurology via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJNeurology logo
The content of VJNeurology is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy